Researchers combine OCT imaging and computational fluid dynamics to accurately map upper airway obstructions, advancing sleep ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Researchers, including experts from the University of Missouri School of Medicine, explored the use of senolytics—drugs ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug ...

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...